AR130727A1 - Compuestos tricíclicos y sus usos - Google Patents
Compuestos tricíclicos y sus usosInfo
- Publication number
- AR130727A1 AR130727A1 ARP230102707A ARP230102707A AR130727A1 AR 130727 A1 AR130727 A1 AR 130727A1 AR P230102707 A ARP230102707 A AR P230102707A AR P230102707 A ARP230102707 A AR P230102707A AR 130727 A1 AR130727 A1 AR 130727A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- tricyclic compounds
- combinations
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona un compuesto, o una sal farmacéuticamente aceptable del mismo, de la fórmula (1), en donde R¹, R², R³, x, R⁴, R⁵, y, R, M, W, L, V, T, Y, J, K y A han sido definidos en la presente, usos terapéuticos de dichos compuestos, usos de dichos compuestos como productos químicos de investigación, una composición farmacéutica y combinaciones que comprenden dichos compuestos, y métodos a elaboración de los compuestos de la invención.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022124865 | 2022-10-12 | ||
| EP22208192 | 2022-11-17 | ||
| US202363494033P | 2023-04-04 | 2023-04-04 | |
| CN2023108913 | 2023-07-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130727A1 true AR130727A1 (es) | 2025-01-15 |
Family
ID=88315575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102707A AR130727A1 (es) | 2022-10-12 | 2023-10-10 | Compuestos tricíclicos y sus usos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240245694A1 (es) |
| EP (1) | EP4601746A1 (es) |
| JP (1) | JP2025536259A (es) |
| KR (1) | KR20250079023A (es) |
| CN (1) | CN120077048A (es) |
| AR (1) | AR130727A1 (es) |
| AU (1) | AU2023361889A1 (es) |
| CL (1) | CL2025001072A1 (es) |
| CR (1) | CR20250187A (es) |
| DO (1) | DOP2025000087A (es) |
| IL (1) | IL319660A (es) |
| JO (1) | JOP20250072A1 (es) |
| MX (1) | MX2025004220A (es) |
| PE (1) | PE20251323A1 (es) |
| TW (1) | TW202417450A (es) |
| UY (1) | UY40470A (es) |
| WO (1) | WO2024079623A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024286830A1 (en) | 2023-06-08 | 2025-12-04 | Nimbus Wadjet, Inc. | Wrn inhibitors |
| EP4755890A1 (en) * | 2023-08-01 | 2026-06-10 | Haisco Pharmaceutical Group Co., Ltd. | Oxo-tricyclic derivative and pharmaceutical use thereof |
| WO2025073792A1 (en) | 2023-10-02 | 2025-04-10 | Forx Therapeutics Ag | Wrn inhibitory compounds |
| AU2024410908A1 (en) | 2023-12-29 | 2026-07-16 | Suzhou Genhouse Bio Co., Ltd. | Fused ring compound, pharmaceutical composition containing same and use thereof |
| TW202539684A (zh) * | 2024-01-15 | 2025-10-16 | 大陸商上海齊魯製藥研究中心有限公司 | 一種三唑並嘧啶類衍生物、其製備方法與應用 |
| WO2025162478A1 (en) * | 2024-02-04 | 2025-08-07 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| TW202547484A (zh) | 2024-04-10 | 2025-12-16 | 瑞士商諾華公司 | 藥物組合及其用途 |
| WO2025218781A1 (en) * | 2024-04-19 | 2025-10-23 | Insilico Medicine Ip Limited | Werner syndrome recq helicase (wrn) inhibitors and methods of uses thereof |
| WO2025223396A1 (en) * | 2024-04-22 | 2025-10-30 | 3H Pharmaceuticals Co., Ltd. | Fused tricyclic compounds and methods of use thereof |
| WO2025232693A1 (en) * | 2024-05-08 | 2025-11-13 | Nuphase Therapeutics (Shanghai) Limited., Co. | Novel compounds, compositions comprising the same and uses thereof |
| WO2025237361A1 (zh) * | 2024-05-16 | 2025-11-20 | 海思科医药集团股份有限公司 | 一种氧代三并环类衍生物及其在医药上的应用 |
| WO2025237389A1 (zh) * | 2024-05-17 | 2025-11-20 | 成都微芯药业有限公司 | 三环wrn抑制剂、其制备方法及其应用 |
| WO2025242186A1 (zh) * | 2024-05-24 | 2025-11-27 | 浙江海正药业股份有限公司 | 氮杂三环类衍生物及其制备方法和用途 |
| WO2025247335A1 (en) * | 2024-05-30 | 2025-12-04 | Allorion Therapeutics Inc | Compounds and use thereof as wrn inhibitors |
| WO2026003380A1 (en) | 2024-06-28 | 2026-01-02 | Forx Therapeutics Ag | Wrn inhibitory compounds |
| CN121426817A (zh) * | 2024-07-10 | 2026-01-30 | 广州科恩泰生物医药科技有限公司 | 一种抑制wrn解旋酶的含氮杂环衍生物、含其的药物组合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5185446A (en) * | 1990-09-04 | 1993-02-09 | Neurogen Corporation | Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| WO2008027990A1 (en) * | 2006-08-29 | 2008-03-06 | Trustees Of Boston University | Therapeutic methods using wrn binding molecules |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| WO2022093820A1 (en) * | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Substituted morpholine compounds |
| AR125966A1 (es) * | 2021-05-26 | 2023-08-30 | Novartis Ag | Nuevos compuestos bicíclicos y sus usos |
| WO2024105610A1 (en) * | 2022-11-18 | 2024-05-23 | Novartis Ag | Pharmaceutical combinations and uses thereof |
| US20260184716A1 (en) * | 2022-11-23 | 2026-07-02 | Novartis Ag | Solid forms of a fused pyridine for the treamtent of cancer |
| US20250368646A1 (en) * | 2024-05-28 | 2025-12-04 | Nimbus Wadjet, Inc. | Tricyclic fused wrn inhibitors |
-
2023
- 2023-10-05 UY UY0001040470A patent/UY40470A/es unknown
- 2023-10-06 TW TW112138548A patent/TW202417450A/zh unknown
- 2023-10-10 CR CR20250187A patent/CR20250187A/es unknown
- 2023-10-10 US US18/483,651 patent/US20240245694A1/en active Pending
- 2023-10-10 AR ARP230102707A patent/AR130727A1/es unknown
- 2023-10-10 WO PCT/IB2023/060166 patent/WO2024079623A1/en not_active Ceased
- 2023-10-10 JP JP2025520852A patent/JP2025536259A/ja active Pending
- 2023-10-10 CN CN202380072193.9A patent/CN120077048A/zh active Pending
- 2023-10-10 EP EP23786776.7A patent/EP4601746A1/en active Pending
- 2023-10-10 AU AU2023361889A patent/AU2023361889A1/en active Pending
- 2023-10-10 IL IL319660A patent/IL319660A/en unknown
- 2023-10-10 PE PE2025000778A patent/PE20251323A1/es unknown
- 2023-10-10 KR KR1020257014873A patent/KR20250079023A/ko active Pending
-
2025
- 2025-04-09 DO DO2025000087A patent/DOP2025000087A/es unknown
- 2025-04-09 CL CL2025001072A patent/CL2025001072A1/es unknown
- 2025-04-09 MX MX2025004220A patent/MX2025004220A/es unknown
- 2025-04-10 JO JOJO/P/2025/0072A patent/JOP20250072A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250079023A (ko) | 2025-06-04 |
| EP4601746A1 (en) | 2025-08-20 |
| CN120077048A (zh) | 2025-05-30 |
| WO2024079623A1 (en) | 2024-04-18 |
| TW202417450A (zh) | 2024-05-01 |
| MX2025004220A (es) | 2025-05-02 |
| PE20251323A1 (es) | 2025-05-16 |
| JOP20250072A1 (ar) | 2025-04-10 |
| CR20250187A (es) | 2025-06-04 |
| UY40470A (es) | 2024-05-15 |
| DOP2025000087A (es) | 2025-06-15 |
| CL2025001072A1 (es) | 2025-08-01 |
| IL319660A (en) | 2025-05-01 |
| US20240245694A1 (en) | 2024-07-25 |
| JP2025536259A (ja) | 2025-11-05 |
| AU2023361889A1 (en) | 2025-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2025000087A (es) | Compuestos tricíclicos y sus usos | |
| PY2240956A (es) | Nuevos Compuestos bicíclicos y sus usos | |
| CL2021003202A1 (es) | Compuestos de pirrolidina | |
| CO2025005872A2 (es) | Compuestos tricíclicos y sus usos | |
| AR116283A1 (es) | Inhibidores del sarcómero cardíaco | |
| CO2024001367A2 (es) | Compuestos antivirales | |
| MX2024009926A (es) | Composiciones y metodos para tratar trastornos del snc. | |
| AR118515A1 (es) | Compuestos y su uso en el tratamiento del cáncer | |
| AR134204A1 (es) | Nuevos compuestos como moduladores de los canales de sodio y usos de los mismos | |
| CO2023002940A2 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| AR125479A1 (es) | Inhibidores de il4i1 y métodos de uso | |
| AR120174A1 (es) | Inhibidores del factor d del complemento para administración oral | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| AR114082A1 (es) | INHIBIDORES DE LA PI4KIIIb | |
| AR134040A1 (es) | Moduladores de mrgprx2 y métodos de tratamiento relacionados | |
| AR128693A1 (es) | Compuestos antivirales y métodos de elaboración y uso de los mismos | |
| CO2023017669A2 (es) | Terapia combinada anti-vhc ventajosa | |
| AR130303A1 (es) | Compuestos de pirazolilsulfonamida y su uso terapéutico | |
| AR114263A1 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| AR124982A1 (es) | Macrociclos y sus usos | |
| AR132445A1 (es) | Moduladores de nk3 y usos de los mismos | |
| AR132539A1 (es) | Compuestos de pirazol 3h-imidazo(4,5-b)piridina y usos de los mismos | |
| AR120654A1 (es) | Macrociclos para uso en el tratamiento de enfermedades | |
| AR134206A1 (es) | Degradantes y usos de los mismos | |
| AR134553A1 (es) | Compuestos y composiciones antivirales y usos de los mismos |